Quality Control Issue Leads to Recall of Allergy Tablets in the US

A significant quality control issue has led to the recall of allergy tablets produced by Unique Pharmaceutical Laboratories, after contamination with ranitidine was discovered. This incident raises serious health concerns, particularly for individuals with sensitivities to ranitidine. The company has taken precautionary measures by recalling four batches of the affected tablets from the US market. Fortunately, no illnesses have been reported so far. This situation highlights the importance of stringent quality control in pharmaceutical manufacturing.

By Narendra Chaudhary Jul 22, 2026, 20:53 IST

Overview of the Recall Incident

A recent quality control issue has emerged involving an Indian pharmaceutical company, which has led to the recall of allergy tablets from American stores. These tablets, commonly used as antihistamines, were discovered to be tainted with a different medication, raising alarms among US health regulators about potential severe reactions, including fatalities.

Details of the Contamination

Unique Pharmaceutical Laboratories, part of J.B. Chemicals & Pharmaceuticals Ltd. based in Mumbai, produces Cetirizine Hydrochloride Tablets USP 5 mg at its facility in Panoli, Gujarat, specifically for the US market. Following the identification of cross-contamination with ranitidine, a medication for heartburn, the company has proactively recalled four batches of these tablets from consumers in the US.

The contamination was first noticed by a pharmacy technician in the US, who observed unusual red spots and discoloration on some tablets while preparing a prescription. This prompted an internal investigation, leading to tests on batches GY825029, GY825030, GY825031, and GY825032. Two of these batches failed to meet safety standards due to unacceptable levels of degradation products. Further analysis confirmed the presence of ranitidine, resulting in the withdrawal of all four batches as a precautionary measure, despite only two failing the tests. The affected products had been distributed between April and June of this year.

Response from the Company and Health Implications

Upon discovering the issue, Unique Pharmaceuticals promptly notified its US distributor, Rising Pharma Holdings Inc., which has since informed its distributors and retail partners about the recall and is facilitating the return of the affected products.

Cetirizine is a popular antihistamine used for treating seasonal allergies and hives, commonly found in many households, often marketed under names like Zyrtec or Cetzine. Ranitidine, previously sold under the Zantac brand, was withdrawn from the market due to safety concerns related to cancer-causing impurities.

While most individuals may not experience significant issues from accidentally consuming a small amount of ranitidine mixed with an allergy tablet, those with known sensitivities could face serious health risks. The company's risk statement warns that exposure could lead to severe allergic reactions or anaphylaxis, which can manifest as a sudden drop in blood pressure, difficulty breathing, swelling of the throat and face, hives, and even loss of consciousness—all of which are potentially life-threatening.

Fortunately, Unique Pharmaceuticals has reported no incidents of illness related to this contamination, indicating that the recall was a precautionary measure rather than a response to confirmed health issues.